Is OTIC or BTI a better dividend investment in 2026?

OTIC currently yields 23529.41% with a 5% 5-year dividend growth rate. BTI yields 5.38% with 5% growth. The better choice depends on your goal: OTIC offers higher current income.

What is the dividend yield difference between OTIC and BTI?

OTIC has a forward dividend yield of 23529.41% ($2.00/share annually). BTI yields 5.38% ($3.15/share annually). The yield gap is 23524.03 percentage points.

Home › Compare › OTIC vs BTI

OTIC vs BTI: Dividend Comparison 2026

OTIC yields 23529.41% · BTI yields 5.38%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 OTIC wins by $263656825893602263040.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

OTIC

● Live price

23529.41%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$263656825893602263040.00M

Annual income

$261,470,826,952,048,300,000,000,000.00

Full OTIC calculator →

BTI

● Live price

5.38%

Share price

$58.47

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.7K

Annual income

$2,786.64

Full BTI calculator →

Portfolio growth — OTIC vs BTI

📍 OTIC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	OTIC	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, OTIC + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

OTIC pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OTIC

Annual income on $10K today (after 15% tax)

$2,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$222,250,202,909,241,040,000,000,000.00/yr

BTI

Annual income on $10K today (after 15% tax)

$457.40/yr

After 10yr DRIP, annual income (after tax)

$2,368.64/yr

At 15% tax rate, OTIC beats the other by $222,250,202,909,241,040,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OTIC + BTI for your $10,000?

OTIC: 50%BTI: 50%

100% BTI50/50100% OTIC

Portfolio after 10yr

$131828412946801131520.00M

Annual income

$130,735,413,476,024,150,000,000,000.00/yr

Blended yield

99.17%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

OTIC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$6.00

+70488.2% upside vs current

Range: $6.00 — $6.00

Altman Z

-16.9

Piotroski

2/9

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.6% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OTIC buys

BTI buys

No recent congressional trades found for OTIC or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricOTICBTI

Forward yield	23529.41% ✓	5.38%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$263656825893602263040.00M ✓	$37.7K
Annual income after 10y	$261,470,826,952,048,300,000,000,000.00 ✓	$2,786.64
Total dividends collected	$263512773352864874496.00M ✓	$14.3K
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Buy	Buy
Analyst price target	$6.00	$40.00 ✓

Year-by-year: OTIC vs BTI ($10,000, DRIP)

Year	OTIC Portfolio	OTIC Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$2,363,641	$2,352,941.18	$11,299	$598.92	+$2.35M → OTIC
2	$522,296,260	$519,767,163.60	$12,794	$703.91	+$522.28M → OTIC
3	$107,898,570,132	$107,339,713,133.69	$14,518	$829.07	+$107898.56M → OTIC
4	$20,839,539,403,669	$20,724,087,933,628.63	$16,513	$978.64	+$20839539.39M → OTIC
5	$3,763,094,738,299,595	$3,740,796,431,137,668.50	$18,827	$1,157.84	+$3763094738.28M → OTIC
6	$635,328,756,192,409,300	$631,302,244,822,428,800.00	$21,518	$1,373.12	+$635328756192.39M → OTIC
7	$100,290,713,829,320,920,000	$99,610,912,060,195,030,000.00	$24,657	$1,632.46	+$100290713829320.89M → OTIC
8	$14,802,844,275,710,542,000,000	$14,695,533,211,913,168,000,000.00	$28,329	$1,945.74	+$14802844275710542.00M → OTIC
9	$2,042,989,665,003,715,000,000,000	$2,027,150,621,628,704,700,000,000.00	$32,637	$2,325.33	+$2042989665003714816.00M → OTIC
10	$263,656,825,893,602,270,000,000,000	$261,470,826,952,048,300,000,000,000.00	$37,708	$2,786.64	+$263656825893602263040.00M → OTIC

OTIC vs BTI: Complete Analysis 2026

OTIC — Stock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Full OTIC Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this OTIC vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OTIC vs SCHD OTIC vs JEPI OTIC vs O OTIC vs KO OTIC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.